“…In addition, the methotrexate (MTX) is also included in the nano-carrier to treat the inflammatory reaction associated with bacterial infection (Lebugle et al, 2002;Alam et al, 2017;Yang et al, 2017;Duan and Li, 2018;Trujillo-Nolasco et al, 2019;Sun et al, 2020). To address the aforementioned issues of bare silver nanoparticles, different nano-carriers have been constructed, such as metalorganic frameworks (MOFs) (Ximing et al, 2017;Zhang et al, 2019Zhang et al, , 2020, hybrid metallic nanoparticles (Mahmoudi and Serpooshan, 2012;Durmus and Webster, 2013;Mei et al, 2013;Shah et al, 2013;Agnihotri et al, 2015;Lim et al, 2015;Kyaw et al, 2017;Kim et al, 2018;Liu et al, 2018;Gasmalla et al, 2019;He et al, 2020;Tong et al, 2020) and mesoporous nanoparticles (Liu et al, 2019). However, the above nano-carriers have some drawbacks, for instance, the low drug loading capacity (<10%) (Cai et al, 2015) and the complexity of designing a multicomponent nano-carrier (containing at least the carrier and two or more compounds).…”